

WORKSHOP AGENDA

Co-Chaired By:

Nils Daulaire, U.S. Department of Health and Human Services
Peter Ndumbe, World Health Organization

Start	End	
Tuesday, 29 November 2011		
Crystal Towers Hotel, Crystal Ballrooms 1,2,3 (Foyer)		
18:00	20:00	Early Registration
Wednesday, 30 November 2011		
Crystal Towers Hotel, Crystal Ballrooms 1,2,3		
7:00	18:00	Registration and Information
8:30	9:00	Workshop Information and Announcements
9:00	9:40	Official Opening
10 Minutes		Welcoming Remarks Precious Matsoso, Department of Health, South Africa
10 Minutes		Welcoming Remarks Workshop Co-chairs
10 Minutes		Overview of Vaccine Capacity Building Stakeholders' Workshop Series and Path Forward for GAP-2 Daniel Miller, U.S. DHHS
10 Minutes		Workshop Goals and Desired Outcomes Peter Ndumbe, WHO
9:40	11:00	SESSION 1: Setting the Stage Moderator: T.S. Rao, Ministry of Science and Technology, India
15 minutes		Presentation 1A: Current and Emerging Public Health Threats: The Importance of Having a Network of Vaccine Producers with Significant Vaccine Production Capacity Presenter: Rick Bright, U.S. DHHS
15 minutes		Presentation 1B: Snapshot of Current Vaccine Manufacturing Capacity Worldwide and Summary of WHO-HHS Activities to Promote Technology Transfer Presenter: Martin Friede, WHO
15 minutes		Presentation 1C: The Need for Sustainable Approaches to Workforce Development Presenter: Akira Homma, Bio-Manguinhos/Fiocruz, DCVMN
15 minutes		Presentation 1D: Mapping the Global Vaccine Manufacturing Workforce: Results of a Survey among Vaccine Manufacturers Presenter: Claudia Nannei, WHO
20 minutes		Q&A and Discussion
11:00	11:20	Morning Break

11:20	12:30	<p>SESSION 2: Vaccine Manufacturing Workforce Training: Lessons Learned and Challenges in Harmonization of Curricula and Identification of Quality Standards</p> <p>Moderator: Pascal Launois, WHO</p>
	15 minutes	<p>Presentation 2A: Toward a Standardized Curriculum for Vaccine Manufacturing Workforce Development</p> <p>Presenter: Kamal Rashid, Utah State University CIB</p>
	15 minutes	<p>Presentation 2B: Identification of Recommended Training Quality Standards</p> <p>Presenter: Tamara Kredo, Global Learning Opportunities/Vaccine Quality</p>
	15 minutes	<p>Presentation 2C: Vaccine Manufacturing Workforce Training: Lessons Learned</p> <p>Presenter: Ruben Carbonell, North Carolina State University BTEC</p>
	20 minutes	Q&A and Discussion
12:30	13:30	Lunch
13:30	14:00	Poster Session
14:00	14:45	<p>SESSION 3: Models and Policies for the Recruitment, Training and Retention of Skilled Local Workforce</p> <p>Moderator: Claudia Nannei, WHO</p>
	15 minutes	<p>Presentation 3A: ILO Strategy for Sector-Based Skills Development</p> <p>Presenter: Ashwani Aggarwal, International Labour Organization</p>
	15 minutes	<p>Presentation 3B: Retention Policies and Models for the Local Workforce</p> <p>Presenter: Morena Makhoana, The Biovac Institute, DCVMN</p>
	15 minutes	Q&A and Discussion
14:45	15:45	<p>SESSION 4: Stakeholder Perspectives – Government Panel</p> <p>Moderator: Guillaume Saour, Ministry of Interior, France</p>
	60 minutes	<p>Panelists:</p> <ol style="list-style-type: none"> 1. Francois Gilardoni, FONGIT Startup Accelerator - FSI Seed Investments, Switzerland 2. Gerardo Guillen, CIGB, Cuba 3. Glaudina Loots, Department of Science and Technology, South Africa 4. Trong Lan Phan, Ministry of Public Health, Vietnam 5. T.S. Rao, Ministry of Science and Technology, India <p>Topics for discussion include:</p> <p>What policies promote availability of a skilled local workforce?</p> <p>Who are the various actors involved in developing and implementing these policies?</p> <p>What policies promote the link between education, training and workforce integration (absorption by the industry)?</p>
15:45	16:15	Afternoon Break

16:15	17:15	<p align="center">SESSION 5: Stakeholder Perspectives - Trainers Panel Moderator: Martin Friede, WHO</p>
	60 minutes	<p>Panelists:</p> <ol style="list-style-type: none"> 1. Nicolas Collin, University of Lausanne, Switzerland 2. Jan Hendriks, RIVM 3. Raf Lemmens, GE Healthcare Life Sciences 4. Srinivasa Rao, Indian Institute of Biotechnology 5. Mark Rohrbaugh, U.S. National Institutes of Health 6. Allan Saul, Novartis Vaccines Institute for Global Health <p>Topics for discussion include:</p> <ul style="list-style-type: none"> Quality Control and Quality Assurance Training Unique role of Centers of Excellence Lessons learned from vaccine manufacturing training providers Example of geographically distributed biomanufacturing training Senior management training and education Business plan and marketing training for DCVMs License negotiations and IP training
17:15	17:30	<p align="center">Day 1 Wrap-up and Announcements Facilitators: Co-chairs</p>
18:30	20:00	<p align="center">Welcome Reception Introduction: Nils Daulaire, U.S. DHHS Remarks: Morena Makhoana, The Biovac Institute, DCVMN</p>

Start	End	
Thursday, 1 December, 2011 Crystal Towers Hotel, Crystal Ballrooms 1,2,3		
8:00	18:00	Registration and Information
8:30	9:30	SESSION 6: Stakeholder Perspectives – Industry Panel Moderator: Erik Iverson, Infectious Disease Research Institute
	60 minutes	<p>Panelists:</p> <ol style="list-style-type: none"> 1. Ze Chen, CNBG, DCVMN 2. GVJA Harshavardhan, Bharat Biotech, DCVMN 3. Norbert Hehme, GSK, IFPMA 4. Akira Homma, Bio-Manguinhos/Fiocruz, DCVMN 5. Patrick Tippoo, African Vaccine Manufacturers Initiative 6. Michael Watson, Sanofi Pasteur, IFPMA <p>Topics for discussion include: The role of the private sector in enhancing international vaccine manufacturing workforce capacity Company marketing and local workforce recruitment strategies to secure the interest and investment of the local community and government(s) Successes in attracting a well-qualified and motivated workforce Challenges in transferring technologies to developing countries</p>
9:30	10:00	SESSION 7: Panel Discussion: Regulatory Panel Moderator: Dr. James Southern, DCVRN
	30 minutes	<p>Panelists:</p> <ol style="list-style-type: none"> 1. Shuang Liu, China State Food and Drug Administration 2. Cathy Parker, Health Canada 3. Satyapal Shani, Central Drugs Standard Control Organisation, India <p>Topics for discussion include: Differences and commonalities between training to NRA staff and manufacturers: how is the training best provided?</p>
10:00	10:30	Morning Break
10:30	11:30	SESSION 8: Panel Discussion: Investments in Capacity Building Moderator: Akira Homma, Bio-Manguinhos/Fiocruz, DCVMN
	60 minutes	<p>Panelists:</p> <ol style="list-style-type: none"> 1. Erik Iverson, Infectious Disease Research Institute 2. Anban Pillay, Department of Health, South Africa 3. Tom Warf, U.S. DHHS <p>Topics for discussion include:</p>

		<p>What type of investment is effective in creating sustainable workforce capacity? When deciding on investments, what role does the investment's impact have on the workforce? What type of data or information is helpful for investors to have in order to make sound decisions?</p>
11:30	12:30	<p>SESSION 9: Panel Discussion: Synergies Among Stakeholders Moderator: Sit Thirapakpoomanunt, Thai GPO, DCVMN</p>
	60 minutes	<p>Panelists:</p> <ol style="list-style-type: none"> 1. Andre Kudlinski, Department of Trade and Industry, South Africa 2. Alexander Ochem, ANDI 3. George Robertson, PATH 4. Beverly Taylor, Novartis, IFPMA <p>Topics for discussion include: How do we promote active collaboration and mutual assistance between stakeholders from different sectors?</p>
12:30	13:30	Lunch
13:30	14:00	Poster Session
14:00	15:00	<p>SESSION 10: Training of Skilled Local Workforce Moderator: Pascal Launois, WHO</p>
	60 minutes	<p>Panelists:</p> <ol style="list-style-type: none"> 1. Ruben Carbonell, North Carolina State University BTEC 2. Ravi Menon, Serum Institute of India 3. Allan Saul, Novartis Vaccines Institute for Global Health 4. T.S. Rao, Ministry of Science and Technology, India 5. Mahendra Suhardono, BioFarma, DCVMN <p>Topics for discussion will include: Discuss the pros and cons of adopting a regional model - pooling regional resources Examine and discuss the working modalities and mechanisms of public/private partnerships Identify ways to enhance appropriate pairings of expertise and infrastructure/facilities</p>
15:00	15:30	Afternoon Break
15:30	16:45	<p>SESSION 11: Stakeholder Concurrent Breakout Sessions Moderator Session A: Daniel Miller, U.S. DHHS Moderator Session B: Michael Watson, Sanofi Pasteur, IFPMA Moderator Session C: Allan Saul, Novartis Vaccines Institute for Global Health</p>

	75 minutes	<p>Objectives of breakout sessions:</p> <ul style="list-style-type: none"> • Facilitate information sharing and networking between DCVMs, academia, and industrial partners • Discuss innovative and cost-effective ways of training those with the greatest need • Exchange ideas regarding how to enhance vaccine manufacturing workforce capacity at both national and regional levels • Factor-in technology evolution when shaping training policies and opportunities <p>Topics for discussion include:</p> <p>Session A: What policies at government level can be implemented to promote workforce training? How to develop a sustainable capacity? How to make sustainable interventions?</p> <p>Session B: What are the current gaps in training? Are these the right trainings? How can we optimize training without risking brain drain? What knowledge, skills, and competencies will be needed to help the vaccine manufacturing workforce maintain their skills as technology evolves?</p> <p>Session C: Is it feasible to develop a core curriculum leading to an internationally recognized diploma/certificate? Can we realistically aim for the creation and recognition of a formal course in vaccinology?</p>
16:45	17:00	<p>Day 2 Wrap-up and Announcements Facilitators: Co-chairs</p>

Start	End	
Friday, 2 December 2011 Crystal Towers Hotel, Crystal Ballrooms 1,2,3		
8:00	11:00	Registration and Information
8:30	10:00	SESSION 12: Reports from Breakout Sessions Moderator: Martin Friede, WHO
15 minutes		Readout from Session A Rapporteur: William Welsh, North Carolina State University BTEC
15 minutes		Readout from Session B Rapporteur: Michael Watson, Sanofi Pasteur, IFPMA
15 minutes		Readout from Session C Rapporteur: Bart Tarbet, Utah State University Institute for Antiviral Research
45 minutes		Q&A and Discussion
10:00	11:00	SESSION 13: Closing Moderator: Daniel Miller, U.S. DHHS
20 minutes		Closing Presentation Parimal Desai, Hilleman Laboratories
20 minutes		Synthesis of Key Points from the Workshop: Workshop Co-chairs
20 minutes		Closing Remarks: Workshop Co-chairs
11:00		Workshop Adjourns